Subsequent Events - Additional Information (Details) - Subsequent Events $ in Millions	1 Months Ended
Oct. 30, 2023 USD ($)
Subsequent Event [Line Items]
Subsequent event description	the Company's collaboration partner, Sanofi, dosed the first patient in the first randomized Phase 2 clinical trial evaluating KT-474. Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the first Phase 2 clinical trial generated a $40 million milestone. Dosing of the first patient in the AD trial will also generate an additional milestone payment to the Company upon occurrence.
Collaboration generated income	$ 40

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration